Cellebrite DI Ltd. (CLBT)
| Market Cap | 2.83B -28.1% |
| Revenue (ttm) | 514.29M +17.8% |
| Net Income | 58.25M |
| EPS | 0.23 |
| Shares Out | 250.79M |
| PE Ratio | 49.17 |
| Forward PE | 18.40 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,597,960 |
| Open | 11.40 |
| Previous Close | 11.49 |
| Day's Range | 11.21 - 11.56 |
| 52-Week Range | 9.58 - 19.98 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 15.36 (+36.05%) |
| Earnings Date | Aug 13, 2026 |
About CLBT
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property thef... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CLBT stock is "Strong Buy." The 12-month stock price target is $15.36, which is an increase of 36.05% from the latest price.
News
Kaplan Fox Notifies Cellebrite DI Ltd. (CLBT) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ...
Kaplan Fox Announces a Securities Investigation into Cellebrite DI Ltd. (CLBT) - Investors Encouraged to Contact the Firm
New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ...
Cellebrite Genesis for Enterprise Now Generally Available, Regional Availability Expands to More Global Markets
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 19, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite says Shiven Ramji to succeed Thomas Hogan as CEO
Cellebrite (CLBT) announced that Shiven Ramji, who joined Cellebrite as President, Products and Technology in May 2026, has succeeded Thomas Hogan as the company’s CEO as part of a planned…
Cellebrite price target lowered to $15 from $23 at TD Cowen
TD Cowen lowered the firm’s price target on Cellebrite (CLBT) to $15 from $23 and keeps a Buy rating on the shares following Q2 results. Cellebrite missed consensus and lowered…
Cellebrite price target lowered to $16 from $20 at JPMorgan
JPMorgan analyst Brian Essex lowered the firm’s price target on Cellebrite (CLBT) to $16 from $20 and keeps an Overweight rating on the shares.
Cellebrite price target lowered to $14 from $20 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Cellebrite (CLBT) to $14 from $20 and keeps a Buy rating on the shares.
Cellebrite price target lowered to $15 from $21 at Lake Street
Lake Street lowered the firm’s price target on Cellebrite (CLBT) to $15 from $21 and keeps a Buy rating on the shares after the company missed its Q2 ARR expectations…
Cellebrite price target lowered to $12.50 from $15 at Needham
Needham lowered the firm’s price target on Cellebrite (CLBT) to $12.50 from $15 and keeps a Buy rating on the shares. Cellebrite made the surprise announcement that Shiven Ramji is…
CLBT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Cellebrite DI Ltd.
Cellebrite DI Ltd. shares dropped over 30% after the Company reported Q2 2026 revenue of approximately $131.1 million and cut its full-year 2026 ARR and revenue guidance -- SueWallSt notifies investor...
Cellebrite DI Earnings Call Transcript: Q2 2026
Q2 ARR grew 21% to $508M but missed guidance due to delayed large deals and lower Inseyets uplift. Revenue rose 16% year-over-year, with strong federal and defense growth. Full-year ARR and revenue guidance lowered, but adjusted EBITDA target raised, reflecting disciplined execution.
Cellebrite DI Earnings release: Q2 2026
Cellebrite DI released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cellebrite DI Slides: Q2 2026
Cellebrite DI has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Cellebrite Appoints Shiven Ramji Chief Executive Officer, Succeeding Thomas E. Hogan
Company Reports Second-Quarter 2026 Results ; Company Lowers Full-Year 2026 ARR and Revenue Outlook and Raises Adjusted EBITDA Target TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 13, 2026 /PRNewsw...
Cellebrite price target raised to $22 from $20 at DA Davidson
DA Davidson analyst Rudy Kessinger raised the firm’s price target on Cellebrite (CLBT) to $22 from $20 and keeps a Buy rating on the shares.
Cellebrite to Report Second-Quarter 2026 Financial Results on August 13, 2026
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 21, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite expands partnership with SkySafe
Cellebrite (CLBT) DI announced an expanded partnership with SkySafe. The exclusive partnership combines advanced digital forensics with advanced drone detection, deep analysis and drone activity, equi...
Cellebrite Expands Exclusive SkySafe Partnership to Deliver Immediate Drone Detection and Airspace Intelligence for Digital Investigations at Scale
The partnership unifies what happens in the sky with what's stored on the drone in a single investigative workflow TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 8, 2026 /PRNewswire/ -- Cellebrite D...
Cellebrite DI Transcript: Mizuho Technology Conference 2026
The session highlighted advanced digital evidence extraction, AI-driven analytics, and a shift to consumption-based models. New products like Genesis expand investigative capabilities, while acquisitions and R&D keep pace with evolving threats and device types. Financial strength and a vertical focus on law enforcement set high barriers to entry.
Cellebrite DI Transcript: Investor update
The platform has evolved from mobile forensics to a comprehensive, AI-powered investigation suite, broadening its user base and accelerating case resolution. New products like Genesis and Guardian Investigate deliver rapid, actionable insights, while robust compliance and technical innovation drive adoption.
Cellebrite Launches the New Age of Investigations with Genesis, Now Generally Available
Reduces investigative workloads from weeks to minutes accelerating investigations like never before TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 10, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite Announces Upcoming Investor Events on June 10, 2026
TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 5, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite DI Transcript: 46th Annual William Blair Growth Stock Conference
The session highlighted a strategic shift to a comprehensive, AI-driven investigative platform, with rapid adoption of new products like Genesis and expanded capabilities through acquisitions. FedRAMP High Authorization positions the company for significant federal opportunities, while AI integration is set to drive both operational efficiency and margin expansion.